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Purpose -  To evaluate left ventricular mass (LVM) in-
dex in hypertensive and normotensive obese individuals.
Methods - Using M mode echocardiography, 544 es-
sential hypertensive and 106 normotensive patients were
evaluated, and LVM was indexed for body surface area
(LVM/BSA) and for height2 (LVM/h2). The 2 indexes were
then compared in both populations, in subgroups strati-
fied according to body mass index (BMI): <27; 27-30;
³30kg/m2.
Results - The BSA index does not allow identification
of significant differences between BMI subgroups. Inde-
xing by height2 provides significantly increased values for
high BMI subgroups in normotensive and hypertensive po-
pulations.
Conclusion - Left ventricular hypertrophy (LVH) has
been underestimated in the obese with the use of LVM/BSA
because this index considers obesity as a physiological
variable. Indexing by height2 allows differences between
BMI subgroups to become apparent and seems to be more
appropriate for detecting LVH in obese populations.
Key words: essential hypertension, obesity, left ventricu-
lar hypertrophy, left ventricular mass index
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Echocardiographic evaluation of hypertensive indivi-
duals is based on preestablished  guidelines for detecting
left ventricular hypertrophy, determined in relation to popu-
lations of normotensive individuals. In turn, the definition
of normal left ventricular mass implies its correction by in-
fluencing physiological factors. Thus, sex, body habitus,
and possibly age are of importance in this correction.
The best index of left ventricular mass is that obtained
using the physiological scale of  weight and height varia-
bles, regarding both men and women.
Therefore, the ideal index would be lean body mass 1,
but this method is not practical and has not been used.
Thus, indexing ventricular mass by body surface area
(BSA) is preferred 2.
However, such an index leads to underestimation of
left ventricular hypertrophy in obese individuals (with a
greater BSA), because its regards obesity as a continuous
physiological variable that would determine increases in
left ventricular mass also on a physiological scale 3.
To correct this, use of mass by height, whose limits are
within the physiological range and thus maintain a normal
and not a pathological relation to ventricular mass, has
been proposed as an index 4-6.
More recent studies 7-11 further suggest that left ventri-
cular mass index should be  determined by height or even
height raised to a power of 2, 2.7, or 2.13, because no first or-
der relation has been demonstrated between height and left
ventricular mass.
In this sense, some selection criteria have been esta-
blished that have been used for the correction of mass by
these proposed indexers (men - 126/143g/m; 49.2g/m2.7;
women - 105/102g/m; 46.7g/m2.7) 4,11. Such criteria, up to
the present, have preferentially been used in larger
population studies 11,13-16 with the purpose of detecting the
impact of the different indexes used on the prevalence of
348
Rosa et al
Left ventricular hypertrophy in obese hypertensive patients
Arq Bras Cardiol
2002; 78: 347-51.
hypertrophy in these populations, known to imply a
worse cardiovascular diagnosis 17-22.
The purpose of the present study is to compare left
ventricular mass index by height squared with the usual
index by body surface area in hypertensive and normotensi-
ve obese individuals.
Methods
In a cross-sectional study, 544 patients with essential
hypertension, 173 men and 371 women, ages ranging from
13 to 84 and 17 to 80 years, respectively, were evaluated as
part of a larger study of cardiac morphometric and functio-
nal evaluation in this group of individuals.
Individuals with a history of mild to moderate hyper-
tension, with or without use of medicines, were selected ba-
sed on a survey of their medical records.
Exclusion criteria were: stage 3 hypertension [systolic
blood pressure (SBP) ³180mmHg and/or diastolic blood
pressure (DBP) ³100mmHg on the day of echocardio-
graphy]; diabetes (with a preestablished diagnosis and/or
fasting glucose ³140mg/dL); chronic renal failure(defined
by serum creatinine ³2.0mg/dL); coronary disease (diagno-
sed through angiography, history of myocardial infarct, an-
gina, or a positive ergometric test); clinical signs of conges-
tive heart failure.
Also, 106 normotensive individuals (51 men and 55
women), whose mean blood pressures, measured on 3 con-
secutive occasions during a 1-week interval, were below
140mmHg (SBP) and 90mmHg (DBP), were evaluated.
The following parameters: age, weight, height, body
mass index23 (BMI:  weight in kg/height2); body surface area2
[BSA:  0.0001 x 71.84x (weight - kg)0.425 x (height -m)0.725]; and
time of hypertension were obtained on the day the echocar-
diogram was performed.
Arterial blood pressure of each hypertensive and
normotensive individual was measured before the examina-
tion, with 1 measurement in the sitting position and 1 after a
5-minute rest.
Regarding the hypertensives, 84.4% of the men and
86.3% of the women were receiving the usual treatment. In
regard to evaluation of pressure levels, 9% had controlled
pressure levels, 7.7% had borderline hypertension, 32.3%
stage 1, and 50.9% stage 2 hypertension according to the
criteria established by the VI Joint National Committee for
prevention and treatment of hypertension 24.
Both hypertensive (HT) and normotensive (NT) groups
were divided into 3 subgroups according to BMI: <27kg/m2
(normal - 79 NT and 287 HT); 27 to 30kg/m2 (overweight - 15
NT and 136 HT); ³30 kg/m2 (obese - 12 NT and 121 HT) 25.
For the echocardiographic evaluation, Escote Biomé-
dica, model SIM5000 equipment, with a mechanical 2.5 MHz
transducer, allowing bi-dimensional M mode evaluation
with pulse and continuous Doppler, was used.
Measures of  left ventricle mass (LVM) were calculated
by  the modified Devereux formula 26: 0.8[1.04(DIVS+ DLVD
+DLVPW)3-(DLVD)3]+0.6, where DIVS, DLVD, and DLVPW
correspond to measurements of  interventricular septum,
left ventricle diameter, and left ventricle posterior wall in
diastole.
All measurements were performed according to the re-
commendations of the American Society of Echocardiogra-
phy 27 that considers measurements at the end of diastole,
including endocardial thickness measures of the septum
and posterior wall. This fact justifies the use of the Ameri-
can Society of Echocardiography (ASE) formula modified
by Devereux 26. This formula brings the left ventricle mass
values obtained by the initially validated ASE formula 28
near those obtained by the Penn convention equation 29,
which, despite being more accurate, uses a less common
method for measurement that excludes the endocardial sep-
tum and wall thickness from the analysis.
For indexing the ventricular mass and calculation of
the prevalence of hypertrophy, body surface area was used,
thus obtaining the LVM/BSA parameter, whose usually
applied normality criteria regarding hypertrophy have been,
110g/m2 in women and 134g/m2 in men 13.
As proposed in the literature 4,5, we also corrected
the mass value by height (LVM/h) and because height 2.7 or
height 2.13 are not practical, we opted for height squared
(LVM/h2).
The prevalence of hypertrophy in the different hyper-
tensive population subgroups was also calculated based on
the mass/height2 limits established for a normotensive refe-
rence population. In this way, using the 95th percentile of
the mass/height2 ratio in this population, the limits of values
of 77.7g/m2 for men and 69.8g/m2 for women were obtained.
For comparison, analysis of prevalence, using the limits of
mass/body surface area obtained through the 95th percen-
tile of the normotensive population, was performed, leading
to 110g/m2 in men and 96g/m2 in women.
Statistical analysis was performed using the Sigma Stat
program. For the global analysis of the demographic, pres-
sure, and cardiac-structural parameters, the values of mean
± standard error were used. The comparative analysis bet-
ween demographic and pressure variables in the 3 different
subgroups of hypertensives and normotensives was per-
formed using a variance test (ANOVA).
For comparison between the cardiac structural para-
meters of the hypertensive and normotensive subgroups,
variance (ANOVA) and covariance tests were necessary,
with adjustment for systolic arterial blood pressure in the
hypertensive and normotensive groups, respectively.
Spearman’s correlation analysis was also used for cor-
relation between anthropometric (weight, height, BSA) and
cardiac structural (LVM/h; LVMh2; LVM/BSA) variables.
Values of p below 0.05 were considered significant.
Results
To test the newly proposed indexer (height), the corre-
lations of anthropometric (weight and height) and derived
(BSA and BMI) parameters with those of cardiac mass, duly
indexed for BSA, height and height2 were obtained. As
shown in Table I, the LVM/BSA variable has a nonsignifi-
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Regarding the other structural variables (LVM/h and
LVM/h2), the LVM/h variable  has a frankly positive relation
to the height variable (r= 0.17) and a correlation of 0.24 with
the body mass index. But when using the correction LVM/
h2, in addition to a better correlation with the body mass in-
dex (r= 0.26), a nonsignificant correlation with the height
variable (r =0.03) was obtained, indicating that the height
variable does not maintain a first order relation to the ventri-
cular mass, as proposed.
Table II shows the demographic and pressure varia-
bles of the hypertensive and normotensive groups accor-
ding to the body mass index distribution.
Figure 1 has the LVM/h2 means in 3 hypertensive sub-
groups. As shown, significantly higher and progressive va-
lues exist in the groups with a higher body mass index.
Comparatively, LVM/BSA evaluation did not show
significant differences with increased BMI.
The same analysis was performed in the normotensive
population, and the results were similar to those of the hy-
pertensive group (Figure 2), although a nonsignificant trend
toward an increase in LVM/BSA parallel to the increase in
BMI has been observed.
Finally, the prevalence of ventricular hypertrophy was
calculated for the 3 hypertensive subgroups, according to
the limited criteria for LVM/BSA and LVM/h2 established on
the basis of the normotensive population. The results (Table
III) show nonsignificant differences in the prevalence of
hypertrophy between the 3 population subgroups when the
correction LVM/h2 (110g/m2 and 96g/m2) was used, but when
the LVM/h2 (77.7 g/m2 and 69.8 g/m2) criterion was utilized,
significant differences between the obese population
subgroup and overweight individuals as compared to with
those with BMI <27g/m2 could be observed.
The utilization of the normally used criteria of LVM/
BSA (134g/m2 and 110g/m2) for calculating the prevalence of
hypertrophy in the hypertensive group, similarly to the 100
and 96g/m2 criteria, also did not show significant differen-
ces between the 3 subgroups (28.2% vs 27.2% vs 24.8%).
Discussion
Obesity is a risk factor known to be important for left
ventricular hypertrophy. The first studies that found an in-
Table I - Correlation between 3 parameters of cardiac mass
correction and measures of body habitus
LVM/BSA LVM/h LVM/h2
Weight 0.07 0.29 * 0.19 *
Height 0.08 0.17 * 0.03
BSA 0.06 0.26 * 0.11 *
BMI 0.03 0.24 * 0.26 *
* p£0.05; LVM/BSA (g/m2) - left ventricular mass corrected by body
surface area; LVM/h (g/m) – left ventricular mass corrected by height;
LVM/h2 (g/m2) – left ventricular mass corrected by height2; BSA (m2) -
body surface area; BMI (kg/m2) - body mass index.
Table II - Demographic and blood pressure parameters in hypertensive and  normotensive individuals according to the distribution of body mass index.
 Normotensive Hypertensive
Kg/m2 < 27 27-30 > 30 P < 27 27-30 >30 P
N 79 15 12 287 136 121
Age 41.2±1.6  44.3± 0.7 43.0± 3.2 NS 50 ± 0.8 51 ±1.07 50 ±1.15 NS
BMI 23.± 0.24 27.9± 0.18 33.3±0.27 < 0.0001 24.3 ± 0.13 28.3 ± 0.07 32.3 ± 0.27 < 0.0001
SBP 110 ±1.2 124 ± 3.4 120 ± 2.1 0.02 148± 1.35 144 ± 1.9 148± 2.13 NS
DBP 80±  0.8 81   ±  1.5 80.0  ±  1.2 NS 92±  0.75 93 ±1.1 95.5 ±1.2 NS
SEX 58.3 / 41.7 51.9 / 48.1 46.3 / 53.3 NS 69.3 / 30.7 66.2 / 33.8 67.8 / 32.2 NS
F/M
BMI (kg/m2)- body mass index; SBP (mmHg)- systolic arterial blood pressure; DBP (mmHg)- diastolic arterial blood pressure
LVM / BSA
Fig. 2 – Cardiac structure evaluation according to body mass index in normotensive.
* p<0.001; LVM/BSA (g/m2) - left ventricular mass/body surface area; LVM/h2 (g/m2)
left ventricular mass/ height2; BMI (kg/m2) - body mass index.
LVM / h2
B M I B M I
Fig. 1 – Cardiac structure evaluation according to body mass index in hypertensive.
* p<0.001; LVM/BSA (g/m2) - left ventricular mass/body surface area; LVM/h2 (g/m2)
- left ventricular mass/height2; BMI (kg/m2) - body mass index.
LVM / h2LVM / BSA
B M I B M I
LVM / h2LVM / BSA
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dependent association between obesity and an increase in
left ventricular mass in the 1960s 30 were later confirmed by
echocardiographic studies 31,32 and reinforced using larger
population studies 9,33-36.
Regarding physiology, obese individuals have an in-
crease in intravascular volume and cardiac output to
supply the increase in metabolic demands related to
increased fatty tissue. In addition, they seem to have an
increase in salt intake 37 and also a greater sympathetic
activity 38, which are both mechanisms participating in the
genesis of left ventricular hypertrophy 37,39.
In addition, obesity is frequently shown to be asso-
ciated with hypertension  40, thus being a risk factor besides
playing a role in adding to 32,41 or increasing hypertension
with respect to cardiac hypertrophy.
The association of obesity with hypertension can also
be seen in studies on body weight reduction that showed
falls in blood pressure levels independent of the use of medi-
cation 42. On the other hand, reduction in left ventricular hyper-
trophy through reduction in body weight independent of falls
in blood pressure levels has been shown, also confirming the
independent role of obesity to cause hypertrophy 43.
Regarding its impact, it has also been demonstrated that
obesity is the most potent predictor of the increase in cardiac
mass, even surpassing the arterial blood pressure factor 8,44.
As has been discussed, the evaluation of the impact of
obesity on hypertrophy in certain populations has been sub-
jected to distortion due to indexing with the body surface area,
leading to an underestimation of hypertrophy in the obese.
Recent studies, among them the LIFE 15 study and the
VITAE 16 study, conducted in Spain, evaluated the impact of
the different selection criteria of the ventricular mass based
on different indexes (BSA, height, height2) and  identified a hi-
gher proportion of obese in the groups where the mass was
indexed by height or height raised to a power.
This fact has already been observed in a few studies that
evaluated the impact of the different indexes on the prevalence
of cardiac structural alterations in their populations 8,11,14,45.
In this study, the analysis of ventricular mass correction
by body surface area did not show significant differences
between the LVM/BSA means of normotensive and hyper-
tensive populations. As already described, the usual correc-
tion of mass by body surface area  implies the underestima-
tion of hypertrophy in the obese, because it considers obesi-
ty as a physiological variable, automatically correcting for
weight and height, as can also be seen in Table I.
On adopting the correction by mass/height2, in a
more practical form than the corrections that use indexed
height raised to a power of 2.13 or 2.7, we observe signifi-
cantly higher mass/height2 values in groups with a higher
body mass index (Figure 1). This correction, although not
being ideal, as well as the correction by lean mass 46, con-
fers a pathological role to the obesity variable, allowing
variations in mass/height2 to occur as a function of wei-
ght, but exclusively according to changes in body fat
(obesity) and not in height. This can be observed in Table
I where nonsignificant correlations of height2 with mass/
heigth2 were obtained.
In view of the fact that mass/height2 criteria are not
defined for the use in hypertensive populations, we obtai-
ned measures for the prevalence of hypertrophy accor-
ding to the use of our own criterion, based on a local po-
pulation. Thus, the use of the correction by mass/height2
can detect significant differences in the prevalence of
overweight and obese populations in relation to indivi-
duals with normal body mass index. This fact was not ob-
served using indexes by mass per body surface area, cor-
roborating previous propositions.
Therefore, we may conclude that, for a more reliable eva-
luation of cardiac hypertrophy in the obese, mainly in popula-
tions at higher risk, such as the hypertensive population, limits
of values of mass/height2 obtained on the basis of normo-
tensive populations, should be used. Thus, we will better de-
tect hypertrophy prevalence in the obese and in this way, better
stratify the cardiovascular risk in a situation where  two  poten-
tial risk factors, obesity and hypertension, are already present.
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